المؤلفون: Merck Sharp & Dohme LLC

المصدر: A Phase 1/2, First-in-human Study of the Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of TT-816 as Monotherapy or in Combination With a PD-1 Inhibitor in Patients With Advanced Cancers (SEABEAM) (MK3475-E88)

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05525455Test

المؤلفون: Tigermed Consulting Co., Ltd

المصدر: First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05498597Test

المصدر: MATCH Treatment Subprotocol Z1F: Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations (PTEN Loss Allowed)

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05490771Test

المصدر: Project 3 - Phase II, Preference Based, Randomized Controlled Trial of Group-Based, In Person Versus Virtual, Cancer Rehabilitation for People With Metastatic / Advanced Breast or Colorectal Cancers

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05424068Test

المؤلفون: Merck Sharp & Dohme LLC

المصدر: Gney GT, Weer LM, Atks MB. Predte bmarkers for checkpot hor-based munotherapy. Lancet Oncol. 2016 Dec;17(12):e542-e551. do 10.1016/S1470-2045(16)30406-5.
Herbst RS, Sor JC, Kowanetz M, Fe GD, Ham O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xo Y, Mokatr A, Koeppen H, Hegde PS, Mellman Chen DS, HodFS. Predte correlates of response to the antPD-L1 antody MPDL3280A cancer patnts. Nature. 2014 Nov 27;515(7528):563-7. do 10.1038/nature14011.
Samste RM, Lee CH, ShoushtarAN, Hellmann MD, Shen R, Janjn YY, Barron DA, Zeh A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, HakAA, Voss MH, Russo P, Rosenberg J, er G, Bochner BH, Bajor DF, Al-Ahmad HA, Chaft JE, Rud CM, Rly GJ, BaxS, Ho AL, Wong RJ, Pfter DG, Wolchok JD, Barker CA, Gut PH, Brennan CW, Tabar V, Mellghoff , DeAngel LM, Aran CE, Lee N, Tap WD, Gounder MM, D'Angelo SP, Saltz L, Stadler ZK, Scher H Baselga J, RazavP, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, LadanyM, RvNA, Berger MF, Rz N, Sol DB, Chan TA, Morr LGT. Tumor mutatnal load predts surval after munotherapy across multle cancer types. Nat Genet. 2019 Feb;51(2):202-206. do 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.
Schumacher TN, Schreer RD. Neoantens cancer munotherapy. Scnce. 2015 Apr 3;348(6230):69-74. do 10.1126/scnce.aaa4971.
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrhard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, LY, ElenahlC, L C, Harbon CT, Wang L, Ras A, Wolchok JD, Chan TA. Genet bas for clal response to CTLA-4 blockade melanoma. N Engl J Med. 2014 Dec 4;371(23):2189-2199. do 10.1056/NEJMoa1406498. Epub 2014 Nov 19. Erratum : N Engl J Med. 2018 Nov 29;379(22):2185.
Vesely MD, Schreer RD. Cancer munoedg: antens, mechanms, and platns to cancer munotherapy. Ann N Y Acad Sc 2013 May;1284(1):1-5. do 10.1111/nyas.12105.
ZappasodR, Merghoub T, Wolchok JD. Emergg Concepts for mune Checkpot Blockade-Based Combatn Theraps. Cancer Cell. 2018 Apr 9;33(4):581-598. do 10.1016/j.ccell.2018.03.005. Erratum : Cancer Cell. 2018 Oct 8;34(4):690.
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, L NU, Lre S, Dancey J, Chen A, HodFS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballger M, Caramella C, de Vrs EGE; RECT workg group. ECT: gueles for response crer for use trls testg munotherapeuts. Lancet Oncol. 2017 Mar;18(3):e143-e152. do 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Erratum : Lancet Oncol. 2019 May;20(5):e242.
Goldmacher GV, KhnanAD, Andtbacka RH Luke JJ, HodFS, Marabelle A, Harrgton K, Perrone A, Tse A, Madoff DC, Schwartz LH. Response Crer for tratumoral munotherapy Sol Tumors: RECT. J Cl Oncol. 2020 Aug 10;38(23):2667-2676. do 10.1200/JCO.19.02985. Epub 2020 Jun 18. No abstract avaable.
A Phase 1b/2a, Open-Label, Multi-Center Study of CyPep-1 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety of CyPep-1 in Patients With Advanced or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC), Melanoma, or Triple-Negative Breast Cancer (TNBC) (CATALYST)

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05383170Test

المؤلفون: Merck Sharp & Dohme LLC

المصدر: A Phase 1, First-in-Human Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Malignancies

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05378425Test

المؤلفون: Oregon Health and Science University

المصدر: An Early Phase I Study of the Pharmacodynamics of WEE1 Inhibitor, ZN-c3, in Metastatic Solid Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05368506Test

المصدر: A Single-arm, Open, Exploratory Clinical Study Evaluating the Safety and Efficacy of EGFR/B7H3 CAR-T in Patients With EGFR/ B7H3-positive Advanced Solid Tumors (Lung and Triple-negative Breast Cancer)

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05341492Test

المؤلفون: National Institute on Aging (NIA)

المساهمون: Carolyn Presley, Principal Investigator

المصدر: Resiliency Among Older Adults Receiving Lung Cancer Treatment (ROAR-LCT): A Phase II Randomized Supportive Care Intervention Clinical Trial

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05339022Test

Other URLs: http://cancer.osu.eduTest

المصدر: A Randomized Phase 2 Study of Atezolizumab With or Without Selinexor in Alveolar Soft Part Sarcoma (AXIOM)

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05333458Test